GlassScriptPhysician profile
Jerald W Koepke
NPI 1477524957
$2,298.06
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $498 · 2021: $488 · 2022: $602 · 2023: $46.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $544.24 | 2019-2022 | |
| Csl Behring | $299.82 | 2019-2022 | |
| Genzyme Corporation | $262.18 | 2019-2022 | |
| Glaxosmithkline, LLC. | $205.96 | 2019-2023 | |
| Aerin Medical INC. | $139.29 | 2022 | |
| Grifols USA, LLC | $124.07 | 2019-2022 | |
| Kaleo, INC. | $108.71 | 2021-2022 | |
| Pfizer INC. | $88.10 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $84.08 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.12 | 2020-2022 | |
| Pharming Healthcare, INC. | $82.57 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $72.06 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $50.81 | 2020 | |
| Genentech USA, INC. | $39.93 | 2022 | |
| Optinose US, INC. | $34.65 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22.58 | 2022 | |
| Phadia US INC. | $20.47 | 2021 | |
| Abbvie INC. | $19.02 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerald Koepke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.